Pulse nav.journalClub Debates activos Tendencias Explorar Preguntas Investigadores

Download the App

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

© Synapse Social LLC, 2026

Política de privacidad

Inicio Explorar nav.journalClub Tendencias

⌘+K

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial | Synapse

September 2, 2021Open Access

Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Based on data from the whole INBUILD trial, nintedanib reduced the risk of events indicating ILD progression.

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Flaherty et al. (Thu,) studied this question.

synapsesocial.com/papers/69de7d976e50a6aba3e93db1 https://doi.org/https://doi.org/10.1183/13993003.04538-2020

Me gusta

Guardar

Compartir

Ver artículo completo

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial2020 · 559 citations
2The natural history of progressive fibrosing interstitial lung diseases2020 · 288 citations
3Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease2015 · 394 citations
4Short‐Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis2017 · 351 citations
5Nintedanib in Progressive Fibrosing Interstitial Lung Diseases2019 · 2,348 citations